Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06973577 · ClinicalTrials.gov registry record · Phase 3
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
A Phase 3 study of Anxiety and ADHD, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 308
- Enrollment target
- 20
- Study locations
NCT06973577: Recruiting Phase 3 study of Anxiety and ADHD, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT06973577 is a Phase 3 study of Anxiety and ADHD that is actively recruiting participants, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 308 participants, below the 439-participant average among 364 other Anxiety trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06973577, a Phase 3 study of Anxiety and ADHD, is actively recruiting participants, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 308 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
Primary Outcome
The AISRS is an 18-item clinician rating scale to evaluate individual ADHD symptoms on a scale of 0 (none) to 3 (severe). The total sum ranges from 0 (no ADHD symptoms) to 54 (extremely severe ADHD symptoms). Negative change from Baseline indicates improvement.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Centanafadine
Study Locations (20)
California
- Clinical Research Site #052 - Leading Edge Research LA, LLC - Encino
- Clinical Research Center #008 - Long Beach Clinical Trial Services Inc. - Long Beach
- Clinical Research Site #008 - Long Beach Clinical Trial Services Inc. - Long Beach
- Clinical Research Site #011 - NRC Research Institute - Orange
- Clinical Research Center #042 - Anderson Clinical Research - Redlands
- Clinical Research Site #037 - Cenexel CIT IE (Clinical Innovations Inc) - Riverside
- Clinical Research Site #039 - California Neuroscience Research, LLC - Sherman Oaks
- Clinical Research Site #038 - Sunwise Clinical Research - Walnut Creek
Florida
- Clinical Research Center #035 - Sarkis Clinical Trials - Gainesville
- Clinical Research Site #005 - Clinical Neuroscience Solutions, Inc. - Jacksonville
- Clinical Research Site #046 - ARSN-Largo CRU - Largo
- Clinical Research Site #010 - Meridien Research/Accel Clinical - Maitland
- Clinical Research Site #015 - Medical Research Group of Central Florida - Orange City
- Clinical Research Site #006 - CNS Healthcare Orlando - Orlando
- Clinical Research Site #019 - Segal Trials Innovatice Clinical Research, Inc. - Tamarac
Arkansas
- Clinical Research Center #033 - Woodland International Research Group - Little Rock
- Clinical Research Center #048 - Woodland Research Northwest - Rogers
Alabama
- Clinical Research Site #017 - Harmonex Neuroscience Research - Dothan
Colorado
- Clinical Research Site #030 - MCB Clinical Research Centers - Colorado Springs
Connecticut
- Clinical Research Site #045 - Research Center for Clinical Studies - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2027-10-04 |
| Phase | Phase 3 |
What NCT06973577 shows while recruiting
NCT06973577 is an interventional study that assigns participants to a tested intervention. The registered 308 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 364 other Anxiety trials with a reported enrollment target (30% lower).
The record links to 4 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06973577 names 20 study sites across 6 states, led by California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06973577 about?
NCT06973577 is a clinical study titled "P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety". Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
What is the current status of trial NCT06973577?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 308 participants. The study started on 2025-03-26. Estimated completion is 2027-10-04.
What conditions does trial NCT06973577 study?
This clinical trial studies the following conditions: Anxiety, ADHD, Social Anxiety Disorder, Generalized Anxiety.
What interventions are being tested in trial NCT06973577?
The interventions under investigation include: Placebo (OTHER), Centanafadine (DRUG).
Who is sponsoring clinical trial NCT06973577?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06973577 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06973577's enrollment target sits among peer trials
308 55th of 364 higher than 309 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
COMPLETED · Phase 3
-
Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth
COMPLETED · Phase 3
-
A Study Comparing Two Treatments for Child With Anxiety
COMPLETED · Phase 3
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- NCT06233942 · 308 participants · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI